| Date | Time | Source | Headline | Symbol | Company |
| 05/06/2024 | 6:25AM | GlobeNewswire Inc. | Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider | NASDAQ:GNTA | Genenta Science SPA |
| 02/12/2024 | 4:05PM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:GNTA | Genenta Science SPA |
| 02/08/2024 | 5:00AM | GlobeNewswire Inc. | Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors | NASDAQ:GNTA | Genenta Science SPA |
| 10/20/2023 | 4:15PM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:GNTA | Genenta Science SPA |
| 09/06/2023 | 7:00AM | GlobeNewswire Inc. | Genenta to Present at Upcoming Scientific and Investor Conferences | NASDAQ:GNTA | Genenta Science SPA |
| 07/28/2023 | 3:00AM | GlobeNewswire Inc. | Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments | NASDAQ:GNTA | Genenta Science SPA |
| 06/29/2023 | 7:00AM | GlobeNewswire Inc. | The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma | NASDAQ:GNTA | Genenta Science SPA |
| 05/25/2023 | 6:04AM | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:GNTA | Genenta Science SPA |
| 05/16/2023 | 7:00AM | GlobeNewswire Inc. | Genenta to Provide Update on Lead Product Temferon™ | NASDAQ:GNTA | Genenta Science SPA |
| 05/12/2023 | 5:13PM | Edgar (US Regulatory) | Securities Registration (foreign Private Issuer) (f-3) | NASDAQ:GNTA | Genenta Science SPA |
| 05/01/2023 | 4:06PM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:GNTA | Genenta Science SPA |
| 04/26/2023 | 7:00AM | GlobeNewswire Inc. | Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing | NASDAQ:GNTA | Genenta Science SPA |
| 04/21/2023 | 5:23PM | Edgar (US Regulatory) | Annual and Transition Report (foreign Private Issuer) (20-f) | NASDAQ:GNTA | Genenta Science SPA |
| 03/10/2023 | 4:49PM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:GNTA | Genenta Science SPA |
| 02/10/2023 | 6:10AM | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:GNTA | Genenta Science SPA |
| 02/01/2023 | 5:29PM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:GNTA | Genenta Science SPA |
| 12/22/2022 | 4:12PM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:GNTA | Genenta Science SPA |
| 10/26/2022 | 6:45PM | TipRanks | Maxim Group Remains a Buy on Genenta Science SpA Sponsored ADR (GNTA) | NASDAQ:GNTA | Genenta Science SPA |
| 10/25/2022 | 5:14PM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:GNTA | Genenta Science SPA |
| 10/03/2022 | 7:17AM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:GNTA | Genenta Science SPA |
| 07/25/2022 | 6:00AM | GlobeNewswire Inc. | AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative | NASDAQ:GNTA | Genenta Science SPA |
| 06/14/2022 | 5:12PM | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:GNTA | Genenta Science SPA |
| 06/15/2009 | 10:47AM | PR Newswire (US) | The following is an investment opinion release issued by EmergingStockReport.com | NASDAQ:GNTA | |
| 05/15/2009 | 10:48AM | PR Newswire (US) | Stock Alerts on Market Movers: NGRN, RMBS, NVLS, LVS, GNTA, AN; Issued by Beacon Equity | NASDAQ:GNTA | |
| 03/06/2009 | 7:36PM | Dow Jones News | Genta: FDA Favors Clinical Trial For Leukemia Drug Genasense | NASDAQ:GNTA | Genta Inc. |
| 03/06/2009 | 6:34PM | Business Wire | FDA Appeal Decision Indicates that Genasense® Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory ... | NASDAQ:GNTA | Genenta Science SPA |
| 02/13/2009 | 4:10PM | Business Wire | Genta Incorporated Announces Fourth Quarter and Year End 2008 Financial Results and Corporate Highlights | NASDAQ:GNTA | Genenta Science SPA |
| 01/07/2009 | 1:02PM | PR Newswire (US) | Beacon Equity Issues Technical Trade Alerts on Newsworthy Market Movers: WLT, SSCC, FNSR, CHTR, STSI, GNTA | NASDAQ:GNTA | |
| 09/15/2008 | 8:05AM | PR Newswire (US) | Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma | NASDAQ:GNTA | |
| 08/07/2008 | 8:00AM | PR Newswire (US) | Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights | NASDAQ:GNTA | |